Advisors Asset Management’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-5,556
| Closed | -$600K | – | 1524 |
|
|
2024
Q3 | $600K | Sell |
5,556
-749
| -12% | -$81.7K | 0.01% | 876 |
|
|
2024
Q2 | $684K | Sell |
6,305
-53
| -0.8% | -$6.25K | 0.01% | 820 |
|
|
2024
Q1 | $839K | Sell |
6,358
-120
| -2% | -$15K | 0.02% | 783 |
|
|
2023
Q4 | $788K | Buy |
6,478
+623
| +11% | +$69.5K | 0.02% | 778 |
|
|
2023
Q3 | $657K | Buy |
+5,855
| New | +$744K | 0.01% | 830 |
|
|
2021
Q4 | – | Sell |
-1,418
| Closed | -$202K | – | 1527 |
|
|
2021
Q3 | $202K | Sell |
1,418
-2,045
| -59% | -$301K | ﹤0.01% | 1206 |
|
|
2021
Q2 | $541K | Sell |
3,463
-37
| -1% | -$5.99K | 0.01% | 982 |
|
|
2021
Q1 | $544K | Sell |
3,500
-49
| -1% | -$7.59K | 0.01% | 997 |
|
|
2020
Q4 | $531K | Sell |
3,549
-45
| -1% | -$6.36K | 0.01% | 950 |
|
|
2020
Q3 | $475K | Sell |
3,594
-50
| -1% | -$6.53K | 0.01% | 934 |
|
|
2020
Q2 | $422K | Sell |
3,644
-52
| -1% | -$5.99K | 0.01% | 949 |
|
|
2020
Q1 | $363K | Buy |
3,696
+825
| +29% | +$108K | 0.01% | 939 |
|
|
2019
Q4 | $417K | Buy |
2,871
+1,130
| +65% | +$156K | 0.01% | 1037 |
|
|
2019
Q3 | $232K | Sell |
1,741
-1,142
| -40% | -$148K | ﹤0.01% | 1155 |
|
|
2019
Q2 | $330K | Sell |
2,883
-1,776
| -38% | -$208K | 0.01% | 1090 |
|
|
2019
Q1 | $578K | Sell |
4,659
-3,005
| -39% | -$341K | 0.01% | 1035 |
|
|
2018
Q4 | $772K | Sell |
7,664
-10,854
| -59% | -$1.22M | 0.02% | 853 |
|
|
2018
Q3 | $2.36M | Sell |
18,518
-12,551
| -40% | -$1.49M | 0.04% | 542 |
|
|
2018
Q2 | $3.36M | Sell |
31,069
-18,208
| -37% | -$1.98M | 0.06% | 404 |
|
|
2018
Q1 | $5.56M | Sell |
49,277
-10,727
| -18% | -$1.25M | 0.09% | 278 |
|
|
2017
Q4 | $7.03M | Sell |
60,004
-5,855
| -9% | -$662K | 0.12% | 223 |
|
|
2017
Q3 | $7.49M | Buy |
65,859
+9,657
| +17% | +$1.11M | 0.13% | 216 |
|
|
2017
Q2 | $7.01M | Buy |
56,202
+11,695
| +26% | +$1.39M | 0.12% | 243 |
|
|
2017
Q1 | $5.28M | Buy |
44,507
+19,361
| +77% | +$2.19M | 0.09% | 323 |
|
|
2016
Q4 | $2.52M | Buy |
25,146
+10,235
| +69% | +$1.1M | 0.04% | 558 |
|
|
2016
Q3 | $1.88M | Buy |
14,911
+9,683
| +185% | +$1.2M | 0.03% | 639 |
|
|
2016
Q2 | $611K | Sell |
5,228
-5
| -0.1% | -$566 | 0.01% | 1033 |
|
|
2016
Q1 | $542K | Sell |
5,233
-7,157
| -58% | -$692K | 0.01% | 1051 |
|
|
2015
Q4 | $1.23M | Sell |
12,390
-6,092
| -33% | -$596K | 0.02% | 825 |
|
|
2015
Q3 | $1.69M | Sell |
18,482
-802
| -4% | -$80.4K | 0.03% | 701 |
|
|
2015
Q2 | $2.04M | Buy |
19,284
+138
| +0.7% | +$15.3K | 0.03% | 660 |
|
|
2015
Q1 | $2.18M | Buy |
19,146
+7,311
| +62% | +$834K | 0.03% | 626 |
|
|
2014
Q4 | $1.3M | Buy |
11,835
+10,898
| +1,163% | +$1.15M | 0.02% | 770 |
|
|
2014
Q3 | $92K | Hold |
937
| – | – | ﹤0.01% | 1474 |
|
|
2014
Q2 | $95K | Hold |
937
| – | – | ﹤0.01% | 1476 |
|
|
2014
Q1 | $86K | Sell |
937
-1,421
| -60% | -$131K | ﹤0.01% | 1477 |
|
|
2013
Q4 | $213K | Sell |
2,358
-147
| -6% | -$12.7K | ﹤0.01% | 1184 |
|
|
2013
Q3 | $200K | Sell |
2,505
-1,886
| -43% | -$148K | ﹤0.01% | 1123 |
|
|
2013
Q2 | $319K | Buy |
+4,391
| New | +$328K | 0.01% | 970 |
|
Other funds holding ZBH
Advisors Asset Management's ZBH Position: Q4 2024 in Review
Advisors Asset Management sold out of Zimmer Biomet (ZBH) in Q4 2024, closing a stake of 5,556 shares — an estimated $600K sold.
Advisors Asset Management first reported a position in ZBH in Q2 2013 and held it in 39 quarters. The position peaked at $7.49M in Q3 2017. 1,027 funds tracked by Wall St. Rank hold ZBH as of Q4 2024.
- Advisors Asset Management reported no remaining Zimmer Biomet position as of Q4 2024 after selling out during the quarter.
- Advisors Asset Management sold 5,556 Zimmer Biomet shares in Q4 2024, an estimated $600K.
- Advisors Asset Management first reported a position in Zimmer Biomet in Q2 2013 and held it in 39 quarters.
- Advisors Asset Management's Zimmer Biomet position peaked at $7.49M in Q3 2017.
- 1,027 funds tracked by Wall St. Rank held Zimmer Biomet as of Q4 2024.
Based on Advisors Asset Management's 13F filing for Q4 2024, filed 10 Feb 2025.